Clinical Trial

Pembrolizumab Plus Lenvatinib in Vulvar Cancer Patients: MITO VULVA-01

Study acronym: MITO VULVA-01
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
MITO VULVA-1 is a prospective, single arm, multi-cohorts, phase II trial that aims to assess the activity and the safety of Lenvatinib plus Pembrolizumab in patients with vulvar cancer. 80 patients will be overall enrolled in the study.Three cohorts are planned
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-12-04.
Status change: Not Yet Recruiting → Recruiting 2026-04-01
Trial Details
NCT Number NCT07290894
Lead Sponsor National Cancer Institute, Naples
Conditions Vulva Cancer
Enrollment 80 participants
Start Date 2026-03-12
Primary Completion 2031-10 (estimated)
Study Completion 2031-10 (estimated)
Updated on ClinicalTrials.gov 2026-04-02